Tag: cannabis

20
Jun 2019

Bionest

Highlights from AAN: Part 2

We continue our report of interesting developments from the American Academy of Neurology meeting:   Neuromyelytis Optica Spectrum Disorder (NMOSD)   Interest in a rare disease called neuromyelytis optica spectrum disorder (NMOSD) appears to be growing. NMOSD is an autoimmune condition that causes swelling of the optic nerve and spinal cord, which can result in...
5
Nov 2018

Bionest

DEA Greenlights Epidiolex Launch with Drug Schedule Reclassification

Earlier this year, we wrote that GW Pharmaceuticals was poised to receive the first approval from the U.S. Food and Drug Administration (FDA) for a drug derived from the cannabis plant — Epidiolex (cannabidiol, also known as CBD), a treatment for seizures related to Lennox-Gastaut syndrome and Dravet syndrome, rare forms of epilepsy. The FDA...
29
May 2018

Bionest

The First Cannabis-Derived Drug Heads for FDA Approval

A new treatment for two particularly severe forms of epilepsy is on track to become the first cannabis-derived drug to gain approval from the U.S. Food and Drug Administration (FDA). On April 19, an FDA advisory panel unanimously recommended the approval of Epidiolex (cannabidiol, also known as CBD), under development by British pharmaceutical company GW...